The present invention relates to a composition comprising at least one plant extract containing at least 0.2% safranal, in particular derived from Crocus Sativus, and at least one probiotic bacterium and/or probiotic yeast, and uses thereof.

Provided is a composition for preventing and treating lipid-related metabolic diseases, the composition comprising, as an active ingredient, Lactobacillus plantarum ATG-K2 or Lactobacillus plantarum ATG-K6 isolated from fermented vegetables.

The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.

The present invention relates to noninvasive microbiome analyses of Barrett's esophagus (BE) patients in which changes in the relative abundance of certain bacteria indicate a disease likelihood or pathogenic state. Additional aspects of the present invention relate to manipulating the microbiome to treat or prevent BE and related conditions. Embodiments also include monitoring for development of disease or monitoring treatment for prevention or elimination of disease states.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.

A composition for the treatment of atopic dermatitis, the composition including, as an active ingredient, Bifidobacterium animalis subsp. lactis LM1017, and more specifically provided is a composition for the treatment of atopic dermatitis. The composition includes, as an active ingredient, a navel Bifidobacterium animalis subsp. lactis LM1017 which adjusts the NF-κB signal transduction pathway, and thus inhibits the expression of proinflammatory cytokines.

Provided is a novel preventive or therapeutic agent for celiac disease. A preventive or therapeutic agent for celiac disease, comprising at least one bacterium belonging to the genus Bifidobacterium selected from the group consisting of Bifidobacterium breve and Bifidobacterium bifidum and/or a processed bacterial cell thereof as an active ingredient.

The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.

The invention relates to a bacterium of the Christensenellaceae family or of a composition containing same for use in the prevention and/or treatment of hypertriglyceridemia in humans or animals.

Provided herein are microbial strains isolated de novo. In some instances, the bacterial strains include genera, species, and/or strains of Lactobacillus johnsonii, Lactobacillus crispatus, Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, and/or Bifidobacterium longum infantis strains. These bacterial strains can be used in the treatment of dysbiosis, inflammation, and other disorders.